1. 于金明 中国 山东第一医科大学 中国工程院院士 Excessive lymph node dissection increases postoperative cardiovascular disease risk in non-small cel..
2. 赫捷 中国 中国医学科学院 中国科学院院士 Efficacy and safety of perioperative sintilimab plus platinum based chemotherapy for potentially res..
3. 于金明 中国 山东第一医科大学 中国工程院院士 Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in the Treatment of Esophageal Squamo..
4. 王俊 中国 北京大学 中国工程院院士 Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter..
5. 郑海荣 中国 南京大学 2023中国科学院院士 Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lu..
6. 钟南山 中国 广州医科大学 中国工程院院士 International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obst..
7. 于金明 中国 山东第一医科大学 中国工程院院士 The treatment in patients with unresectable locally advanced non-small cell lung cancer: Exploration..
8. 赫捷 中国 中国医学科学院 中国科学院院士 International expert consensus on immunotherapy for early-stage non-small cell lung cancer
9. 赫捷 中国 中国医学科学院 中国科学院院士 Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under diffe..
10. 赫捷 中国 中国医学科学院 中国科学院院士 Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
11. Ross A,Soo 新加坡 National University Health System A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mu..
12. Byoung Chul,Cho 韩国 Yonsei University A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mu..
13. Martin,Reck 德国 Grosshansdorf Hospital A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mu..
14. Peters, Solange 瑞士 CHU Vaudois A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mu..
15. Rolf A,Stahel 瑞士 University of Zurich A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mu..
16. Girard, Nicolas 法国 Hospital of Civils Lyon Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and ..
17. Fred R,Hirsch 美国 University of Colorado Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding que..
18. 陆舜 中国 上海交通大学医学院 主任医师 Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding que..
19. Peters, Solange 瑞士 CHU Vaudois Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding que..
20. Ramaswamy,Govindan 美国 University of Washington Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding que..